Prostate Cancer Clinical Trials Consortium

The Prostate Cancer Clinical Trials Consortium (PCCTC) is a 13-member clinical research group sponsored by the Prostate Cancer Foundation and the Department of Defense Prostate Cancer Research Program (PCRP), with its Coordinating Center headquartered at Memorial Sloan-Kettering Cancer Center.

Visit the PCCTC site for trial information: www.pcctc.org

---

Open Trials

Janssen Biotech, Inc. is sponsoring an advanced prostate cancer research study. This study will evaluate the effectiveness of an investigational drug plus prednisone to determine if there is a decrease in Prostate-Specific Antigen (PSA). The study will also evaluate whether this combination prolongs the time until it is evident that the cancer has spread. Additionally, safety information will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last. You may be eligible for the study if you:

• Are eighteen years of age or older
  
• Have been diagnosed with prostate cancer
  
• Are currently receiving, and have had continuous therapy with, Gonadotropin-releasing hormone (GnRH) monotherapy for at least 6 months or have undergone surgical removal of the testicles

To learn more about this study, please visit www.prostatecancerstudynow.com

---

 

Additional open trials can be found by going to:

 

 

 

 

 

 

 

 

 Literature:

 Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials

Tomasz M. Beer, MD
Larry Axmaker, Ed.D.

Written from both a patient and clinician perspective by Larry Axmaker, Ed.D., and Tomasz M. Beer, MD, a PCF-funded researcher, this book is an insightful resource for anyone considering clinical trials in addition to standard cancer therapy.   Order Here »

 

Also, visit our Clinical Trials FAQ.